Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Beam Therapeutics (BEAM – Research Report), Cormedix (CRMD – Research Report) and Applied Therapeutics (APLT – Research Report).
Beam Therapeutics (BEAM)
In a report issued on May 7, Luca Issi from RBC Capital maintained a Hold rating on Beam Therapeutics, with a price target of $35.00. The company’s shares closed last Friday at $21.26, close to its 52-week low of $16.95.
According to TipRanks.com, Issi is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Beam Therapeutics is a Moderate Buy with an average price target of $46.67, representing a 104.9% upside. In a report issued on May 8, Barclays also maintained a Hold rating on the stock with a $33.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Cormedix (CRMD)
In a report issued on May 9, Gregory Renza from RBC Capital maintained a Buy rating on Cormedix, with a price target of $9.00. The company’s shares closed last Friday at $5.17.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
Currently, the analyst consensus on Cormedix is a Strong Buy with an average price target of $12.67, implying a 134.6% upside from current levels. In a report released yesterday, Truist Financial also maintained a Buy rating on the stock.
Applied Therapeutics (APLT)
In a report issued on May 9, Brian Abrahams from RBC Capital maintained a Buy rating on Applied Therapeutics, with a price target of $12.00. The company’s shares closed last Friday at $4.39.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
Applied Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $11.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BEAM:
- Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
- Beam Therapeutics price target lowered to $33 from $42 at Barclays
- Beam Therapeutics reports Q1 EPS ($1.21), consensus ($1.42)
- Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
- Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
